secwatch.observer — SEC 8-K summary
======================================

Issuer:     Denali Therapeutics Inc. (DNLI)
CIK:        0001714899
Form:       8-K
Filed at:   2025-01-07T23:59:59+00:00
Accession:  0001714899-25-000007
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali's DNL343 fails Phase 2/3 ALS trial; primary endpoint not met
-------------------------------------------------------------------

- Primary endpoint of ALSFRS-R and survival at 24 weeks not met vs placebo.
- Key secondary endpoints (muscle strength, respiratory function) also not statistically different.
- DNL343 was safe and well tolerated overall.
- Additional analyses including NfL biomarkers and subgroup data expected later in 2025.
- Trial enrolled 186 DNL343-treated vs 139 placebo participants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1714899/000171489925000007/0001714899-25-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1714899/000171489925000007/dnli-20250106.htm
  HTML page:      https://secwatch.observer/filing/0001714899-25-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer